Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

SupraSense Development of Suprasensors and Assays for Molecular Diagnostics

Coordinator
Karlsruher Institut Fuer Technologie, Germany
Runs
1 July 2023 to 30 June 2028
Status
Running
EU funding
€2.0m
Total cost
€2.0m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101088734

What the project is doing

In the project's own words, from its summary on CORDIS.

SupraSense combines completely new strategies to design and realize biomimetic artificial receptors for bioactive small molecules, i.e. metabolites, with the aim of overcoming long-standing selectivity and sensitivity limitations that hindered other synthetic sensory systems from reaching diagnostic applications. Sophisticated yet easy to fabricate “SupraSensors” will be developed based on unprecedented hybrid zeolitic materials whose binding cavities are modulated by peptide-based cofactors, thereby mimicking enzyme pockets.

SupraSensors will be functional and directly applicable for molecular diagnostics in urine, saliva, and blood and will be of utility in point-of-care units and personal homes. Emphasis is given to the detection of metabolites that are important disease indicators. I am an expert on “conventional” synthetic chemosensors and have studied both their merits and fundamental shortcomings. Out of this deep routed analysis, I developed the proposed ambitious strategy that marries principles of molecular recognition with materials science and chemistry-informed deep learning.

These SupraSensors will advance the field through the following elements: i) high-energy water release from microporous materials ensures high binding affinity; ii) strategically placed peptide-based recognition elements provide selectivity while offering synthetic tunability; iii) information-rich signal output from SupraSensor libraries enables metabolite distinction in biofluids; iv) novel signal amplification concepts increase sensitivity.

SupraSensor discovery will be fast and generalizable to many metabolite classes. SupraSense has the potential to unleash supreme opportunities for multiparameter diagnostics, which will be essential for patient subgrouping based on metabolic phenotypes. The new concepts developed herein have the prospect to revolutionize early detection of emerging cardiovascular events, inflammations, sepsis, and other metabolic or aging-associated diseases.

Topics

Who is involved

OrganisationCityCountryRole
Karlsruher Institut Fuer TechnologieKarlsruheGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI